Acute small fiber neuropathy after Oxford-AstraZeneca ChAdOx1-S vaccination: A report of three cases and review of the literature

Acute small fiber neuropathy after Oxford-AstraZeneca ChAdOx1-S vaccination: A report of three cases and review of the literature

Introduction Small fiber neuropathy usually presents with gradual and progressive chronic length-dependent pain. Acute small fiber neuropathy is rarely reported. Three patients with acute onset neuropathic pain after Oxford-AstraZeneca ChAdOx1-S vaccination are described. Patients and Methods Two p...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Abbott, MG, Allawi, Z, Hofer, M, Ansorge, O, Brady, S, Fadic, R, Torres, G, Knight, R, Calvo, M, Bennett, DLH, Themistocleous, AC
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	Wiley 2022

Antzeko izenburuak

Alopecia areata following ChAdOx1 nCoV-19 vaccination (Oxford/AstraZeneca)
nork: Hsuan-An Su, et al.
Argitaratua: (2022-10-01)

Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
nork: Marek Mikołajczyk, et al.
Argitaratua: (2022-12-01)

Thromboembolism and the Oxford-AstraZeneca vaccine
nork: Perera, R, et al.
Argitaratua: (2021)

AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy
nork: Syed B. Ali, et al.
Argitaratua: (2022-03-01)

Superficial Thrombophlebitis of the Penis following AstraZeneca ChAdOx1-S Vaccination: A Rare Venous Thromboembolic Complication
nork: Joshua Winston, et al.
Argitaratua: (2022-03-01)

Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases
nork: Craig Peter Coorey, et al.
Argitaratua: (2022-11-01)

Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
nork: Jennifer Serwanga, et al.
Argitaratua: (2024-01-01)

Vaccine‐induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine–A case report
nork: Bader Al Rawahi, et al.
Argitaratua: (2021-08-01)

Membranoproliferative Glomerulonephritis following the Oxford AstraZeneca COVID-19 Vaccine
nork: Kawtar Hassani, et al.
Argitaratua: (2021-01-01)

Malaysia to use AstraZeneca vaccine
nork: Povera, Adib
Argitaratua: (2021)

Vaccine-induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCoV-19) vaccine: report of two cases
nork: Rita Carlotta Santoro, et al.
Argitaratua: (2022-05-01)

Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in Vietnamese healthcare workers
nork: Van Vinh Chau, N, et al.
Argitaratua: (2021)

Busting the Breast Cancer with AstraZeneca’s Gefitinib
nork: S. Chemmalar, et al.
Argitaratua: (2023-01-01)

Case Report of Serum Sickness-like Reaction following the First Dose of the Chimpanzee Adenovirus-Vectored AstraZeneca COVID-19 Vaccine, ChAdOx1
nork: Areej Awad Alzaidi, et al.
Argitaratua: (2023-02-01)

Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in Vietnamese health-care workers
nork: Chau, NVV, et al.
Argitaratua: (2022)

Humoral anti-SARS-CoV-2 immune response for different strains after Sinovac-CoronaVac and Oxford/AstraZeneca (ChAdOx1-S) full vaccination on a healthcare population in Brazil
nork: Maicon Jeferson Silva de Oliveira, et al.
Argitaratua: (2024-03-01)

COVID-19 outbreak response at a nursing hospital in South Korea in the post-vaccination era, including an estimation of the effectiveness of the first shot of the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1-S)
nork: Chanhee Kim, et al.
Argitaratua: (2022-04-01)

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
nork: Josue Antonio Estrada, et al.
Argitaratua: (2022-04-01)

Oxford-AstraZeneca Coronavirus Disease-2019 Vaccine-Induced Immune Thrombocytopenia on Day Two
nork: Azhar Kareem Razzaq, et al.
Argitaratua: (2021-01-01)

Bioethical Crossroads: the Case of the Oxford- AstraZeneca azd1222 Vaccine Against covid-19
nork: Fabio Alberto Garzón Díaz
Argitaratua: (2024-08-01)

Sobre la vacuna desarrollada en Reino Unido (Universidad de Oxford-AstraZeneca)
nork: Álvaro Danza, et al.
Argitaratua: (2021-04-01)

Adverse effects of Oxford-AstraZeneca COVID-19 vaccine among Egyptian healthcare workers
nork: Mai Al Kaffas, et al.
Argitaratua: (2022-10-01)

Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca‐Oxford COVID‐19 vaccine
nork: Mona Al‐Ahmad, et al.
Argitaratua: (2021-08-01)

Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study
nork: Jehad Aldali, et al.
Argitaratua: (2023-01-01)

Pregnant and Breastfeeding Mothers Who Have Received the ChAdOx1 AstraZeneca COVID-19 Vaccine May Have Infants with an Increased Risk of Zinc Insufficiency and SCID Disease
nork: Amr Ahmed, et al.
Argitaratua: (2023-03-01)

Lipschütz ulcers after AstraZeneca COVID-19 vaccination
nork: Maria Bracho-Borro, et al.
Argitaratua: (2023-08-01)

The first report of myocarditis followed by AstraZeneca vaccination in Iran
nork: Karo Servatyari, et al.
Argitaratua: (2022-06-01)

Acute rejection following COVID-19 vaccine (AstraZeneca)
nork: Prem P Varma, et al.
Argitaratua: (2022-01-01)

Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm
nork: Enayat Anvari, et al.
Argitaratua: (2022-09-01)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
nork: Waleed H. Mahallawi, et al.
Argitaratua: (2021-12-01)

New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination
nork: Amira Muftah, et al.
Argitaratua: (2024-12-01)

Rhabdomyolysis following Oxford/AstraZeneca COVID-19 vaccination; two case reports from Iran
nork: Marzieh Hashemi, et al.
Argitaratua: (2024-01-01)

Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy
nork: Konstantina Salveridou, et al.
Argitaratua: (2024-09-01)

Turun padang daftar vaksin AstraZeneca untuk warga emas
nork: Utusan Borneo Sabah
Argitaratua: (2021)

New Tendencies in the Development of the EU Competition Law – the AstraZeneca case
nork: K. V. Entin
Argitaratua: (2011-10-01)

Relationships and Activities. The study is supported by OOO AstraZeneca Pharmaceuticals.
nork: E. V. Shlyakhto, et al.
Argitaratua: (2023-07-01)

A case of Thrombotic Thrombocytopenic Purpura following the AstraZeneca Vaccine
nork: Effat Iranijam, et al.
Argitaratua: (2022-12-01)

Amyotrophic neuralgia secondary to Vaxzevri (AstraZeneca) COVID-19 vaccine
nork: J.A. Crespo Burillo, et al.
Argitaratua: (2021-09-01)

Rapid whole‐blood assay to detect SARS‐CoV‐2‐specific memory T‐cell immunity following a single dose of AstraZeneca ChAdOx1‐S COVID‐19 vaccine
nork: Katie E Lineburg, et al.
Argitaratua: (2021-01-01)

Pityriasis rosea-like rash after COVID-19 vaccination with Oxford-AstraZeneca: a possible trigger?
nork: Fernando Eibs Cafrune, et al.
Argitaratua: (2023-01-01)